Clinical Trial: The Effect of 0.5% Roxithromycin Lotion for Androgenetic Alopecia

Study Status: Withdrawn
Recruit Status: Unknown status
Study Type: Interventional

Official Title: The Study for New Effect of Roxithromycin on Androgenetic Alopecia.

Brief Summary: The purpose of this study is exploiting the new drugs for androgenetic alopecia because there are still no effective and safe topical drug for androgenetic alopecia. Roxithomycin is one of the macrolide antibiotics that has immunomodulatory effects. We firstly found that roxithromycin increases the rate of murine and human hair follicle elongation in vitro. Therefore, we apply this drug on this disease therapy.

Detailed Summary: The topical therapy for androgenetic alopecia is still not enough to improve cosmetically. Thereforem we try to find new effective and safe topical therapy for this disease. Roxithromycin has not only antibacterial action but also immunomodulatory and anti-inflamatory potency. For example, roxitromycin inhibits T cell responces to mitogens and production of cytokines, IL-2 and IL-5. We firstly found that roxitromycin increased human and murine hair elongation in vitro to inhibit apoptosis of hair bulb. Then, we wish to apply roxithromycin on the therapy for androgenetic alopecia.
Sponsor: Hamamatsu University

Current Primary Outcome:

Original Primary Outcome: The hair elongation after 1 week of application. Cosmetical improvement. Evaluation by dermoscopy

Current Secondary Outcome: Pathological study taken from lesional scalp skin. [ Time Frame: One year ]

Original Secondary Outcome: Pathological study taken from lesional scalp skin.

Information By: Hamamatsu University

Dates:
Date Received: September 12, 2005
Date Started: May 2005
Date Completion: January 2007
Last Updated: July 28, 2010
Last Verified: April 2005